Objective: To identify factors that independently contribute to disability and quality of life (QoL) in patients with mild to moderate Parkinson disease (PD).
There has been a recent surge of interest in determinants of functional outcome in Parkinson disease (PD). Systematic reviews of longitudinal studies 1,2 have identified older age at onset, postural instability and gait difficulty (PIGD), bradykinesia, lack of tremor at disease onset, depression, and early cognitive impairment as prognostic factors for rapid decline in disability. Evidence for the role of axial impairment (PIGD) in predicting future disability in PD is particularly compelling. 2 In addition, cognitive abilities, includ-ing visuoconstructive skills, 3 attention, 4 set-shifting, 5 and verbal fluency, 6 were reported to be associated with disability in PD.
Evaluations of quality of life (QoL) are also increasingly used as an outcome measure in clinical trials and epidemiologic studies on PD. 7 Compared with the general population, patients with PD report lower levels of QoL in terms of physical, social, and emotional functioning. 8 Depression was found to be the most consistent determinant of reduced QoL in PD. 9 There are, however, some limitations in this literature. Several studies have conducted univariate analyses only, and thus were unable to determine the independent contribution of prognostic variables to functional outcome. The cognitive evaluation was limited in most studies. In addition, several factors that may be expected to influence disability and QoL, such as comorbidity and social support, have rarely been evaluated.
We explored the relative contributions of multiple potential predictors to disability and QoL in patients with PD using multivariate analyses. We hypothesized that axial impairment would be strongly associated with disability, and that mood symptoms would be a primary determinant of QoL.
METHODS Subjects. The study population comprised 202 patients with PD who participated in the baseline assessment of an ongoing longitudinal project investigating the course of functional decline in PD. Details of the case-finding procedure have been published elsewhere. 10 In brief, consecutive patients with newly diagnosed PD recruited from the neurology outpatient clinics of six general hospitals in Amsterdam and surrounding area in the Netherlands were included (n ϭ 133). In addition, patients were identified from the medical records and from the Dutch Parkinson's Disease Association (n ϭ 69). A diagnosis of PD was confirmed by the project neurologist, based on standard clinical criteria. 11 Exclusion criteria were age Ն85 years and the presence of somatic illness with a life expectancy of less than a year.
Procedure. The study was approved by the local ethics committees of the participating hospitals. Written informed consent was obtained from all subjects after the nature of the study was explained. All patients underwent neurologic and neuropsychological examinations, either in the hospital or at their home, between July 2002 and April 2005.
Assessments. Explanatory factors. Demographic and clinical characteristics. A semi-structured interview was used to obtain data about age, marital status, education, age at onset of PD, current medication, and duration of PD (time between the appearance of the first symptom as reported by the patient and the moment of assessment). The stage of disease was determined with the Hoehn & Yahr rating scale. 12 The Cumulative Illness Rating Scale (CIRS) 13 was administered during history taking to assess comorbidity. This validated scale 14 rates the severity of comorbid diseases for 13 organ systems (range 0 -52, higher scores indicating more severe comorbidity).
Motor, cognitive, and affective symptoms. The severity of extrapyramidal symptoms was rated using the motor section of the Unified Parkinson's Disease Rating Scale (UPDRS). 15 This scale was subdivided into six domains to obtain scores for specific motor symptoms: facial expression, tremor, rigidity, bradykinesia, speech, and axial impairment. 16 Furthermore, based on the UPDRS motor section, patients were classified in one of three clinical subtypes: akinetic-rigid, tremor-dominant, and mixed (features of akinetic-rigid and tremor). 17 In addition to assessment of global cognitive functioning (Mini-Mental State Examination [MMSE]) 18 and premorbid intellectual ability (National Adult Reading Test, Dutch version [DART]), 19 we administered 17 neuropsychological tests to evaluate five cognitive domains: attention and psychomotor speed, language, declarative memory, executive function, and visuospatial abilities (table 1). 20 Given the large number of tests, composite z-scores for each domain were calculated. All test measures were transformed into normally distributed z-scores using the Van der Waerden method. Subsequently, composite scores were computed for each cognitive domain by taking the mean of z-scores from the individual tests that contributed to the particular domain. Higher z-scores indicate better cognitive performance. The validity of this test classification was found to be satisfactory (Cronbach ␣ Ͼ 0.7 for each cognitive domain, except for language, as only one test was used to assess this domain).
The Hospital Anxiety and Depression Scale (HADS), 21 which has demonstrated validity in PD, 22 was used as screening instrument of affective symptoms. This self-administered 14-item questionnaire is particularly suited for the assessment of affective status in patients with PD since it contains no somatic items. In addition to the HADS total score, separate scores can be calculated for the depression (HADS-D) and anxiety (HADS-A) subscales. The proposed cut-off values were used to classify patients as unimpaired (not anxious or not depressed, scores Յ7 on each subscale), or having possible (scores 8 -10 on each subscale) or probable (Ն11 on each subscale) mood symptoms.
Social factors. The Social Support Scale was used to assess the perceived availability of support (range 12-60, higher scores indicating lower social support). 23 Outcome measures. Disability was assessed with three scales: the Schwab and England ADL (SE-ADL), 24 the AMC Linear Disability Score (ALDS), 25, 26 and the Functional Independence Measure (FIM). 27 The SE-ADL is specifically designed to assess ADL in patients with PD on a scale ranging from 0% (bedridden) to 100% (completely independent), with 10% intervals. The ALDS is a generic instrument which includes ADL and instrumental activities of daily living (IADL) items hierarchically ordered from simple (e.g., "pushes a chair to the table") to complex ("travel by local bus, tram, or subway"). The total score range is 0 to 100, with higher scores indicating better functional ability. The ALDS has been found to have adequate clinimetric properties in patients with PD. 28 The FIM, which has demonstrated validity for assessment of functional ability, 29 contains 18 items that focus on motor or cognitive activities (range 18 -126, higher scores indicating greater ADL independence).
QoL was evaluated with a disease-specific instrument, the Parkinson's Disease Quality of Life questionnaire (PDQL), 30 and a generic measure, the SF-36. 31 The PDQL, which has adequate clinimetric support, 32 is a selfadministered measure which contains 37 items allocated to four subscales: parkinsonian symptoms, systemic symptoms, social functioning, and emotional functioning. The total PDQL score is 37-185, with higher scores indicating better QoL. The SF-36 measures eight health dimensions from which two summary scores can be derived, the physical and mental component (range 0 -100, higher scores indicating better health status).
Statistical analysis. Demographic and disease-related
characteristics were summarized with descriptive statistics. 2 , Mann-Whitney, and Kruskal-Wallis tests were used for comparison between groups, when appropriate.
Spearman rank correlation coefficients were calculated to assess the association between explanatory variables and measures of disability and QoL. Because we wanted to determine the contribution of specific motor symptoms and cognitive abilities to functional outcome, the UPDRS total score and the MMSE score were excluded from the analysis.
All significant (p Ͻ 0.05) univariately associated explanatory variables were stepwise entered into linear multiple regression models with measures of disability and QoL as the dependent variables. Analyses were performed using SPSS version 11.0. The level of significance was set at p Ͻ 0.05, unless otherwise indicated. In view of the explorative nature of this study we did not correct for multiple comparisons. 33 RESULTS Description of study population. Of the original 202 patients, 190 completed all assessments and were included in the present analysis. No differences in terms of demographic and clinical characteristics, disease severity, HADS score, MMSE performance, or comorbidity were found between patients who did and those who did not participate in the study. Patients who were excluded, however, exhibited greater severity of extrapyramidal symptoms as measured with the UPDRS motor section.
Demographic and clinical characteristics and functional outcome of the patients are shown in table 2. Patients were affected by PD on average for 3.3 years. Most patients (70%) had moderate disease severity (i.e., Hoehn and Yahr stages 2-3). Based on the HADS-A scores, 21% of patients showed possible anxiety symptoms and 9.5% displayed probable anxiety. The HADS-D scores indicated that 15% of the patients exhibited possible and 8% probable depressive symptoms. In most patients (97%) MMSE performance was within the normal range.
Twenty-one percent of patients were not receiving any medication at time of the assessment, 54% were treated with levodopa alone or in combination with other drugs, 39% were taking a do- pamine agonist, 4% amantadine, 4% entacapone, and 2% an anticholinergic medication. To calculate total levodopa amount, different drugs were pooled in a levodopa equivalent dose (LED). 34 Determinants of disability and poor QoL. Those variables shown to be associated with disability and reduced QoL were submitted to stepwise multiple linear regression models (table e-2). Axial impairment accounted for 31% of the variance of SE-ADL score. Increasing bradykinesia and masked facial expression also contributed to the model. The full model explained 35% of the variance of SE-ADL scores. The ALDS was most strongly associated with axial impairment, but also higher comorbidity contributed to the model. The full model explained 37% of the variance of ALDS. Using the FIM as the dependent variable, axial impairment was again identified as the primary contributor. Additional contributing factors were comorbidity, masked facies, and impairment in executive function. To identify the specific components that accounted for the relationship between the composite executive domain score and the FIM, a multiple regression analysis was repeated with individual tests of executive function as the explanatory variables together with all of the factors retained in the initial analysis and with FIM scores as the dependent variable. This analysis revealed that semantic fluency task made a unique contribution to the FIM (p Յ 0.001). The full model explained 45% of the variance in FIM scores.
The PDQL total score was primarily associated with mood symptoms and axial impairment. Increasing bradykinesia, higher comorbidity, and levodopa dosage contributed additionally to reduced QoL. The full model explained 63% of the variance in total PDQL score. When the HADS-D and HADS-A subscales were entered into the model instead of the overall HADS score, both depression and anxiety were found to be related to the PDQL, to a similar extent.
The PDQL parkinsonian symptoms subscale was primarily related to axial impairment and Values are mean Ϯ SD (range) or n (%). *Dutch Adult Reading Test. 19 mood symptoms. Increasing bradykinesia and duration of PD as well as higher comorbidity also contributed to the model. The PDQL systemic symptoms subscore was most strongly associated with affective symptoms. Additional proportion of the variance was explained by higher comorbidity and levodopa dosage, and the presence of akinetic-rigid clinical subtype of PD. The PDQL dimension of social functioning was most affected by mood symptoms and axial impairment. Additional contributing factors were increasing bradykinesia, higher comorbidity and levodopa dosage, and performance on tests of attention and psychomotor speed. Further analysis revealed that performance on the Stroop test color naming condition accounted for the relationship between attention/processing speed and social functioning. The emotional functioning subscale of the PDQL was primarily related to mood symptoms. Increasing bradykinesia was the only additional factor that influenced emotional functioning. The proportion of explained variance in the final models ranged from 40% for PDQL systemic symptoms to 58% for PDQL emotional functioning.
The SF-36 physical component was primarily related to axial impairment. Additional variance was explained by higher comorbidity and longer duration of PD. The full model accounted for 27% of the variance in SF-36 physical component. The only factor that contributed to SF-36 mental component was the degree of mood symptoms.
DISCUSSION
The present study has four main findings. First, axial impairment (PIGD) was strongly associated with disability in this sample of patients with mild to moderate PD. While accounting for other potential contributors, axial symptoms alone explained 31-37% of the variance in disability as measured with one diseasespecific (SE-ADL) and two generic rating scales (ALDS, FIM). Second, self-reported mood symptoms and axial impairment were the main determinants of worse QoL. Third, comorbidity contributed consistently to disability and QoL beyond the contribution made by demographic and clinical features of PD. Fourth, cognitive changes had little impact on functional outcome once the effect of motor and mood symptoms had been taken into account.
As hypothesized, axial impairment contributed most to disability, consistent with a recent review of the literature, 2 in which greater severity of PIGD was found to be a major predictor of rapid progression of disability in PD over time.
After accounting for the effects of overall disease severity as measured with the Hoehn and Yahr scale, axial impairment still emerged as the strongest contributor to disability in each of the three final models in this study. In addition, bradykinesia, comorbidity, and masked facies were also independently associated with greater disability, but the magnitude of their effects was rather modest.
The hypothesis that mood symptoms would contribute more to reduced QoL than other features of PD was substantiated. In our sample, subjective complaints about mood problems, as measured with the HADS, accounted for the largest proportion of variance in the PDQL summary score, PDQL dimensions of systemic symptoms, social and emotional functioning, and emerged as the only independent contributor for the SF-36 mental component. A strong relationship between the HADS and psychosocial/emotional aspects of QoL in particular is likely to be due in part to the similar content measured with these instruments. Moreover, the assessments of affective status and QoL both relied on self-report, and this may have artifactually increased the extent of their association. However, a strong relationship between mood symptoms and QoL in patients with PD has also been demonstrated in studies using clinician-rated instruments of affective status, 35 making this explanation less likely. Furthermore, depression and anxiety are common and biologically plausible symptoms of PD. 36, 37 Therefore, it is conceivable that these emotional symptoms contribute to changes in functional outcome in PD. It is important to note that a standardized diagnostic interview or a formal psychiatric assessment was not conducted in this study, so the classification accuracy of affective problems of the HADS cannot be ensured. Nonetheless, there is some evidence suggesting that characterization of mood disturbances in PD on a continuum using rating scales may better capture the effect of depression on functional outcome than the use of fixed diagnostic criteria. 38 Along with mood complaints, PIGD were identified as an important determinant of poor QoL, which is in accordance with other studies. 39 For the PDQL parkinsonian symptoms subscale and the SF-36 physical component, axial impairment was the primary contributor. Additional factors included comorbidity and bradykinesia, which independently contributed to five and four out of the seven QoL indices in this study. Disease duration and levodopa dosage had small impact on some components of QoL, which is consistent with some previous reports. 40 The role of comorbidity has rarely been addressed in previous studies examining determinants of functional outcome in PD. In this study, comorbidity made a small, but significant contribution to functional status, both in terms of disability and QoL, even after accounting for the effects of demographic and disease-related characteristics of PD.
In our sample, the impact of cognitive performance on functional outcome appeared to be minimal. Only performance on verbal fluency tasks was related to one of the three disability measures. This finding supports a recent study, 6 in which verbal fluency emerged as an independent determinant of disability in nondemented patients with PD. Our findings are in contrast to the few existing studies in the literature, in which tests of attention, 4 set-shifting, 5 and visuoconstructive skills 3 were found to be associated with disability in PD. A possible explanation for this discrepancy is that these previous reports studied PD patients with dementia, 4 used informantbased assessment of ADL status, 5 or conducted only univariate analyses, 3 whereas in the present study self-reported measures of disability were employed in a sample with overall mild cognitive dysfunction and the independent impact of multiple determinants was examined simultaneously.
Regarding the effect of cognitive changes on QoL, only tests of attention/psychomotor speed made a small contribution to the PDQL social functioning dimension. One possible explanation for the absence of this association may lie in overall mild nature of cognitive impairment in our sample and the relatively limited range of QoL scores, which may have reduced the likelihood of obtaining a statistically significant relationship.
The apparent lack of effects of social support on disability and QoL is puzzling and raises questions concerning the usefulness of the Social Support Scale. The validity and reliability of the Social Support Scale in measuring the quality of social support in the PD population needs to be established before implementing this scale in further studies.
Strengths of the present study are the relatively large PD sample, a standardized assessment of motor function, affective status and functional capacity, the use of both disease-specific and generic measures of disability and QoL, the extensiveness of the neuropsychological examination, and the fact that multiple potential explanatory factors were considered simultaneously in the analysis. Some limitations of this study should also be recognized. First, the majority of patients in our study formed a clinic-based sample, which may be subject to selection bias. However, these patients were recruited from six different general neurologic clinics and additional patients were included via the Dutch Parkinson's Disease Association. Nevertheless, our sample comprised mainly patients with mild to moderate PD, thus limiting the generalizations of the present findings to the population of patients with PD in advanced stages of the disease. Second, a cross-sectional design of this study with all assessment conducted at one point in time precludes inferences about causality. Third, it is important to note that despite multiple predictors considered in the present analyses, there was still a large proportion of unexplained variance in disability and in some QoL measures. This is likely due to the characteristics of our sample, which included patients with PD with well preserved independence in most daily activities.
